Massive Bio, a cancer patient matchmaker, has been selected by the Precision Cancer Consortium to help identify potential candidates for clinical trials.
The consortium, founded in 2022, is focused on promoting data-driven precision oncology as a “new normal’ for cancer patients and increasing access to targeted “next generation sequencing” testing and tailored interventions, the group said in a June 2 press release.
The group is currently made up of AstraZeneca, Bayer, Eli Lilly, GSK, Johnson & Johnson/Janssen, Novartis and Roche.
Massive Bio’s platform uses artificial intelligence to help patients find clinical trials relevant to their specific cancer much faster while also helping fill an industry need to identify and include more diverse populations in trials.
“Our technology utilizes genomics and clinical data from various platforms to present available intervention options for each patient in order to optimize clinical trial matching by reducing inefficiencies and multiple screenings,” Arturo Loaiza-Bonilla, M.D., Massive Bio co-founder and chief medical officer, said in the release. “Together, we can help more patients access the right treatment options and improve outcomes."
Financial terms of the collaboration weren’t disclosed.
Under the agreement, Massive Bio is tasked with designing and running a trial matching tool for prospectively matching patients through genomic testing and clinical data through a set of selected ongoing biomarker-driven clinical trials at specific locations.
The two groups will also investigate larger scale or real-world applications for the future.